A transformative partnership between Lunit and Labcorp promises to accelerate digital pathology innovations through artificial intelligence. By combining Lunit’s expertise in AI-driven cancer diagnostics with Labcorp’s extensive laboratory services, the collaboration aims to support new breakthroughs in oncology research and clinical care.

The U.S. Food and Drug Administration has requested additional information from Telix Pharmaceuticals regarding its experimental diagnostic tool for a form of kidney cancer. This development underscores the regulatory rigor that emerging medical products must meet before approval.